MEIRAGTX
Live / Registered — Registered (as of 17 Feb 2026)
What this means for you
Registered since 17 Feb 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99023559
- Registration number
- 8140892
- Mark type
- Stylized text
- Filed
- 30 Jan 2025
- Published for opposition
- 30 Dec 2025
- Registered
- 17 Feb 2026
- Attorney of record
- Michael J. Leonard
Goods and services
- Class 001 — Chemicals: chemical additives, namely, chemical auxiliary agents, carriers, and substances, all for use in the manufacture of pharmaceutical preparations
- Class 005 — Pharmaceuticals: pharmaceutical products for use in gene therapy; pharmaceutical preparations and substances for the treatment of neurological and neurodegerative diseases, ocular diseases and rare diseases, in the nature of rare kidney diseases, rare cardiovascular diseases, rare hepato-gastro-enterological diseases, rare immunodeficiencies, developmental defects, neuromuscular diseases, rare neurological diseases, rare cardiovascular diseases, rare lung diseases, rare bone diseases, rare sensory disorders, rare skin diseases, rare diseases of connective tissue, rare endocrine diseases, rare hereditary metabolic diseases, rare nonmalignant hematologic disorder, salivary gland conditions, oncology, autoimmune conditions, ageing, metabolic disease, obesity; auxiliary agents for pharmaceutical preparations, namely, small molecule compounds for use as drug delivery agents in pharmaceuticals; carriers for pharmaceutical preparations, namely, drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals; substances for pharmaceutical preparations, namely, namely, anti-infectives, anti-inflammatories, antibacterial pharmaceuticals, antibiotics, antifungal preparations, and antivirals; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; dermatological pharmaceutical preparations and substances; pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations and substances for ophthalmological use; pharmaceutical preparations and substances for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations and substances for the prevention and treatment of bone diseases, salivary gland conditions, oncology, autoimmune conditions, aging, metabolic disease, and obesity; biological preparations for use in cell cultures for medical purposes
- Class 040 — Treatment of materials: Custom manufacture of human therapeutics, pharmaceuticals, biologicals and biopharmaceuticals
- Class 042 — Scientific and technological services: scientific research in the field of genetics, gene therapy and genetic engineering; genetic testing for scientific research purposes; scientific advisory services relating to gene therapy research; scientific, biological, pharmaceutical and medical research services; laboratory research in the fields of genetics, drug development, biotechnology, microbiology and molecular biology; biochemical and biotechnological analysis services
Owner
- MeiraGTx Limited, London, GB
- MeiraGTx Limited, London, GB
- MeiraGTx Limited, London, GB
Prosecution history
- 17 Feb 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 17 Feb 2026 — REGISTERED-PRINCIPAL REGISTER
- 30 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Dec 2025 — PUBLISHED FOR OPPOSITION
- 24 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Nov 2025 — EXAMINER'S AMENDMENT ENTERED
- 10 Nov 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 10 Nov 2025 — EXAMINERS AMENDMENT E-MAILED
- 10 Nov 2025 — EXAMINERS AMENDMENT -WRITTEN
- 15 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 15 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 15 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 21 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 21 Jul 2025 — NON-FINAL ACTION E-MAILED